Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin Symlin dose titration trial

Executive Summary

Amylin will submit results of a dose titration study for Symlin in 250 type-1 diabetes patients as an amendment to its NDA in the second-half of 2002. Patients will be followed for six months after a one month period of pramlintide titration; insulin adjustments will be allowed throughout the study, as requested by FDA's Endocrinologic & Metabolic Drugs Advisory Committee July 26 (1"The Pink Sheet" July 30, 2001, p. 5). The dosing data is expected to be included in labeling. Amylin is also conducting short pharmacokinetic and pharmacodynamic trials. Symlin received an "approvable" letter Oct. 12 requesting additional clinical data (2"The Pink Sheet" Oct. 15, 2001, In Brief)...

You may also be interested in...



Symlin “Approvable” Letter Will Be Addressed By Ongoing Trials, Amylin Says

Amylin hopes that data from two ongoing open-label Symlin trials will address questions outlined by FDA in an "approvable" letter for the diabetes agent

Symlin "approvable" letter

Amylin will conduct additional trials of antidiabetic Symlin (pramlintide) prior to approval. The trials could focus on dose titration. Amylin is discussing clinical protocol for further studies with FDA after the agency deemed the product "approvable" Oct. 12

Amylin Symlin Study Will Evaluate Hypoglycemia Risk During Dose Initiation

Amylin is planning a six-week Symlin safety study to evaluate the increased incidence of hypoglycemia associated with the antidiabetic agent, the company said following a July 26 FDA advisory committee recommendation against approval of the drug.

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel